Rep. Thomas H. Kean, Jr. Unloads Shares of Stryker Corporation (NYSE:SYK)

Stryker logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Rep. Thomas H. Kean Jr. reported selling $1,001–$15,000 of Stryker shares on October 27 from a State Street Bank & Trust account; he also disclosed several other stock trades.
  • Stryker’s latest quarterly results slightly missed expectations: EPS was $3.52 versus $3.55 forecast, and revenue was $6.52 billion versus $6.62 billion expected, though revenue rose 7.6% year over year.
  • Director Ronda Stryker sold 550,000 shares for about $178.9 million. Analysts’ average rating remains “Moderate Buy,” with an average price target of $343.77.
  • MarketBeat previews the top five stocks to own by December 1st.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation NYSE: SYK. In a filing disclosed on November 19th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on October 27th. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

  • Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 10/27/2026.
  • Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 10/27/2026.
  • Sold $1,001 - $15,000 in shares of Warner Bros. Discovery NASDAQ: WBD on 10/7/2026.
  • Sold $1,001 - $15,000 in shares of Stryker NYSE: SYK on 9/30/2026.
  • Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 9/30/2026.
  • Purchased $1,001 - $15,000 in shares of ESAB NYSE: ESAB on 9/29/2026.
  • Sold $1,001 - $15,000 in shares of Mondelez International NASDAQ: MDLZ on 9/23/2026.
  • Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 9/17/2026.
  • Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 9/17/2026.
  • Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 8/27/2026.

Stryker Stock Performance

Shares of Stryker stock opened at $313.17 on Friday. The company has a market capitalization of $119.22 billion, a PE ratio of 22.28, a P/E/G ratio of 2.18 and a beta of 0.78. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18. The company has a 50-day simple moving average of $294.97 and a two-hundred day simple moving average of $321.64. Stryker Corporation has a one year low of $267.00 and a one year high of $389.33.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same quarter in the prior year, the business posted $3.19 earnings per share. The firm's quarterly revenue was up 7.6% on a year-over-year basis. Research analysts expect that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Stryker news, Director Ronda Stryker sold 550,000 shares of the stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the transaction, the director owned 1,701,375 shares in the company, valued at approximately $553,491,315. This represents a 24.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.60% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on SYK shares. Citigroup reaffirmed a "market outperform" rating on shares of Stryker in a report on Friday, October 30th. Barclays lowered their price objective on Stryker from $375.00 to $365.00 and set an "overweight" rating for the company in a research report on Friday, October 30th. Robert W. Baird dropped their target price on Stryker from $385.00 to $334.00 in a research note on Friday, October 30th. Wall Street Zen downgraded Stryker from a "buy" rating to a "hold" rating in a research note on Saturday, October 3rd. Finally, Stifel Nicolaus decreased their price target on Stryker from $330.00 to $325.00 and set a "buy" rating for the company in a research note on Monday, November 2nd. Twenty-one analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $343.77.

Read Our Latest Research Report on SYK

Hedge Funds Weigh In On Stryker

A number of institutional investors have recently modified their holdings of SYK. State Street Corp boosted its holdings in Stryker by 1.7% during the third quarter. State Street Corp now owns 15,799,557 shares of the medical technology company's stock worth $4,364,738,000 after buying an additional 266,992 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company's stock valued at $2,571,357,000 after acquiring an additional 45,478 shares during the period. Bank of America Corp DE purchased a new position in shares of Stryker in the 2nd quarter valued at about $1,404,284,000. Royal Bank of Canada increased its stake in shares of Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock valued at $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Stryker by 21.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company's stock valued at $846,723,000 after purchasing an additional 481,175 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Stryker

(Get Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company's products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines